The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
Open accessAbstract
BACKGROUND: Peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more compelling in gastrointestinal cancers, very little is known of their impact on breast cancer. We investigated the association between the NLR and PLR, and overall survival after breast cancer. METHODS: Data from the University of Malaya Medical Centre Breast Cancer Registry was used. Of 2059 consecutive patients diagnosed from 2000 to 2008, we included 1435 patients with an available pre-treatment differential blood count (∼70%). Patients were stratified into quintiles of the NLR/PLR. Multivariable Cox regression was used to determine the independent prognostic significances of the NLR/PLR. RESULTS: Compared with the first quintile of the NLR, women in quintile 5 were younger, had bigger tumours, nodal involvement, distant metastases and higher tumour grades. Higher NLR quintiles were significantly associated with poorer survival with a 5-year relative survival ratio (RSR) of 76.4% (95% CI: 69.6-82.1%) in quintile 1, 79.4% (95% CI: 74.4-83.7%) in quintile 2, 72.1% (95% CI: 66.3-77.3%) in quintile 3, 65.6% (95% CI: 59.8-70.8%) in quintile 4 and 51.1% (95% CI: 43.3-58.5%) in quintile 5. Following adjustment for demography, tumour characteristics, treatment and the PLR, the adjusted hazard ratio (HR) for quintile 5 vs quintile 1 was 1.50 (95% CI: 1.08-1.63); Ptrend=0.004. Results were unchanged when the NLR was analysed as a dichotomous variable using different cutoff points. Although patients in PLR quintile 5 had lower survival than in quintile 1 (5-year RSR: 53.2% (95% CI: 46.9-59.2%) vs 77.0% (95% CI: 70.9-82.2%)), this association was not significant after multivariable adjustment. However, a PLR >185 was significantly associated with poorer survival; adjusted HR: 1.25 (95% CI: 1.04-1.52). CONCLUSIONS: Both the NLR and PLR are independently associated with an increased risk of mortality in breast cancer. Their added value in the prognostication of breast cancer in clinical practice warrants investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Cancer survival in five continents: a worldwide population-based study (CONCORD)
Coleman, M. P., Quaresma, M., Berrino, F., Lutz, J.-M., De Angelis, R., Capocaccia, R., Baili, P., Rachet, B., Gatta, G., Hakulinen, T., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70179-7 · Cited by 1,002
Roxburgh, C. S., & McMillan, D. C. (2010) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 998
Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer
Walsh, S. R., Cook, E. J., Goulder, F., Justin, T. A., & Keeling, N. J. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20329 · Cited by 894
Regression models for relative survival
Dickman, P. W., Sloggett, A., Hills, M., & Hakulinen, T. (2004) · Statistics in Medicine · doi:10.1002/sim.1597 · Cited by 792
Cited by
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Ethier, J.-L., Desautels, D., Templeton, A., Shah, P. S., & Amir, E. (2017) · Breast Cancer Research · doi:10.1186/s13058-016-0794-1 · Cited by 673
The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis
Liang, W., & Ferrara, N. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0313 · Cited by 347
The neutrophil-to-lymphocyte ratio: a narrative review
Socorro Faria, S., Fernandes Jr, P. C., Barbosa Silva, M. J., Lima, V. C., Fontes, W., Freitas-Junior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 332
Zheng, J., Cai, J., Li, H., Zeng, K., He, L., Fu, H., Zhang, J., Chen, L., Yao, J., Zhang, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485396 · Cited by 260
Metadata
- Authors
- Koh, C.-H., Bhoo-Pathy, N., Ng, K.-L., Jabir, R. S., Tan, G.-H., See, M.-H., Jamaris, S., & Taib, N. A.
- Venue
- British Journal of Cancer
- Published
- 2015-05-28
- Volume
- 113
- Issue
- 1
- Pages
- 150-158
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1586470106
- Cited by
- 327
- References
- 37
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. https://app.cochat.ai/papers/10.1038/bjc.2015.183
- The paper
- Koh, C.-H., Bhoo-Pathy, N., Ng, K.-L., Jabir, R. S., Tan, G.-H., See, M.-H., Jamaris, S., & Taib, N. A. (2015). Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2015.183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.